GlassScriptPhysician profile
Prashanth S Rao
NPI 1841462694
$3,596.89
in general payments reported to CMS, 2019-2025
28 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $219 · 2021: $491 · 2022: $632 · 2023: $553 · 2024: $444 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375 · Education: $99.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.34 |
| Education | $99.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $528.69 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $448.49 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $414.53 | 2019-2025 | |
| Novo Nordisk INC | $294.31 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $251.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $225.38 | 2021-2025 | Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.55 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $131.95 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $131.93 | 2022-2023 | |
| Baxter Healthcare | $112.59 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $91.99 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.01 | 2019-2025 | Lifevest |
| Arbor Pharmaceuticals, INC. | $85.49 | 2019-2021 | |
| Medtronic, INC. | $84.94 | 2021 | |
| Amgen INC. | $79.29 | 2019-2025 | Repatha, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $66.56 | 2019 | |
| Sanofi-Aventis U.S. LLC | $50.35 | 2019 | |
| Esperion Therapeutics, INC. | $48.40 | 2024-2025 | Nexletol |
| Abbott Laboratories | $45.33 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amarin Pharma, INC. | $37.76 | 2020-2022 | |
| Boston Scientific Corporation | $34.59 | 2023 | Watchman |
| Actelion Pharmaceuticals US, INC. | $26.57 | 2024 | Opsumit |
| Philips North America LLC | $24.39 | 2024 | (Ck4) Mcot |
| Irhythm Technologies, INC. | $21.79 | 2022 | |
| Heartflow, INC. | $20.57 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.71 | 2024 | Arcalyst |
| Shield Therapeutics INC | $18.60 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashanth Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.